In a multicenter retrospective analysis of lorlatinib in 37 heavily pretreated, ALK+ advanced NSCLC patients, median lorlatinib DOT was 4.4 months, with 43.2% ORR and median OS from lorlatinib onset lasting 10.2 months [24]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.